DOCSLIB.ORG

Developing Nations Struggle to Obtain Sufficient Vaccines UN Security Council Calls for Improved Access Agence France-Presse Recent Surveys Have Shown Pa Newspaper

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Developing Nations Struggle to Obtain Sufficient Vaccines UN Security Council Calls for Improved Access Agence France-Presse Recent Surveys Have Shown Pa Newspaper HHEADLINESEADLINES MONDAY March 1, 2021 3 Developing nations struggle to obtain sufficient vaccines UN Security Council calls for improved access Agence France-Presse Recent surveys have shown pa newspaper. vaccine confi dence remains low, “The prospects for recovery Manila/Washington with almost half of the population are diverging dangerously across The Philippines received 600,000 reportedly unwilling to be inocu- countries.” vaccine doses from China on Sun- lated against the coronavirus. To There were also reminders of day, kick-starting the country’s boost trust, several top offi cials the months ahead, with new vi- inoculation drive, despite con- — including the health minister — rus cases increasing again global- cerns about the Sinovac jab’s ef- are expected to receive the Coro- ly after a month in which they had fectiveness. naVac jab. fallen by half. Top government offi cials and President Duterte, who has de- The global death toll is now health workers will be the fi rst on fended Chinese-made vaccines, above 2.5 million out of a total of Monday to receive the Chinese- suggested he will be inoculated in some 113 million cases. made vaccine — called CoronaVac public, having previously said he In Brazil, several cities and — just days after the drug regulator would receive it in private. states imposed a new round of approved it for emergency use. The rollout came as the num- curfews and restrictions in a bid President Rodrigo Duterte, ber of daily new infections in to contain a surge of cases. whose government has been un- the Philippines hit a four-month The country, whose death toll der fi re over delays in procuring high. More than 570,000 cases passed 250,000 Thursday, has vaccines, oversaw the delivery of have been confi rmed, including had a piecemeal response to the the doses at a military air base. over 12,000 deaths. crisis, with local authorities set- Around 525,000 doses of the Aside from hospital work- ting policies as far-right Presi- AstraZeneca jab were also due to ers, the military is set to receive dent Jair Bolsonaro dismisses re- arrive Monday as part of the CO- 100,000 Sinovac doses. strictive measures and the use of VAX global inoculation program Members of the Philippines face masks. and will also be off ered to health- armed forces are required to get Estonia was forced to ban church care workers. The regulator did vaccinated and those who refuse services and to close theatres and not recommend CoronaVac for could be disciplined. museums, while the Czech gov- healthcare workers due to its The government is in talks with ernment said it would stop people comparatively low effi cacy. seven vaccine makers, including from leaving their local districts An advisory group to the Phil- Sinovac, in the hope of securing and shut all schools and shops sell- ippine government allowed it to enough doses to inoculate 70 mil- ing non-essential goods. be off ered to those willing to take lion people — about 60 percent of There was unanimous support it, but many nurses and doctors the population — this year. for a resolution at the United Na- are reluctant and have opted to But the bulk of the supply is tions Security Council calling for wait for other vaccines. not expected to start arriving un- improved access to vaccines in In the Philippine General Hos- til the summer. confl ict-hit and impoverished pital, one of the country’s main Many developing countries countries. facilities treating COVID-19 pa- have struggled to secure supplies In a rare gesture, it was cospon- tients, only 10 percent of staff were and launch inoculations, and sored by all 15 members of the willing to be inoculated with the there have been repeated warn- council, diplomats said, and re- Chinese-made vaccine, spokes- ings over the consequences. quired just a week of negotiations man Jonas Del Rosario told AFP. In Africa, Ivory Coast received to draft. It was far from the 94 percent its fi rst jabs — a consignment of “We are all facing the same who registered to take the Pfi zer- half a million doses funded by the threat, the same pandemic, and BioNTech jab, said Del Rosario, Covax initiative for poorer coun- international cooperation and who himself opted not to take the tries. And just over half of the multilateral action is needed,” CoronaVac shot. population of Israel has now had one diplomat said. The hesitancy is not new in the at least a fi rst dose. But Tedros Adhanom Ghe- Southeast Asian nation, which Russia and Austria have mean- breyesus, head of the World has struggled with vaccine pro- while agreed to talks over the de- Health Organization, reacted grams in recent years. livery and joint production of by saying richer countries must The Philippines was the fi rst Russia’s Sputnik V vaccine. waive intellectual property rights country in 2016 to deploy the The economic recovery will on vaccines so more manufactur- dengue vaccine Dengvaxia, but a be “long and uncertain”, Inter- ers can start production. botched rollout led to unfounded national Monetary Fund chief The idea is fi ercely opposed by claims that several dozen chil- Kristalina Georgieva warned in many wealthy countries and the dren had died from the jab. an interview with Italy’s La Stam- pharmaceutical industry. Indonesian athletes eye tournaments aft er receiving COVID-19 vaccine Ramadani Saputra The Jakarta Post/Jakarta A Friday gathering at Istora Senayan in Central Jakarta was the fi rst time in a year the sports arena hosted athletes after a frus- trating hiatus due to the COV- ID-19 pandemic. But those hundreds of athletes, representing various sports, were not there to compete. They were lined up to receive their fi rst jab of a COVID-19 vaccine as part of the second phase of the government’s vaccination program. Swimmer I Gede Siman Sud- artawa, who specializes in back- stroke, said he planned to go Antara/Aditya Pradana Putra straight to the gym after receiving Immunity booster: Indonesian national soccer player Miftahul the jab, saying he was not feeling Hamdi (left) receives his fi rst shot of the COVID-19 vaccine during any side eff ects. a national inoculation session held at Istora Senayan in the Gelora “I asked [the health workers] Bung Karno sports complex, Central Jakarta, on Friday. if I could exercise after this, and they said yes as long as I don’t still haven’t been able to compete.” received their fi rst jab at Friday’s experience any side eff ects. But In his last test, the 20-year-old event at Istora Senayan. if, for example, I get a headache, recorded one of his personal bests So far, only the national bad- they suggested that I get some by clocking in at 6.40 seconds for minton and tennis teams are set rest,” he said on Friday. 60 meters of an 100 m race. De- to send their athletes to interna- Echoing Siman, sprinter Lalu spite the achievement, he said he tional tournaments soon. Muhammad Zohri cheerfully said still had to improve his skills, espe- After taking part in the Asian he only felt a little sore on the spot cially in the last 40 m, as he felt that leg, consisting of three consecu- where he had received the shot nerves would likely get the best of tive tournaments in Thailand in in his arm. him in the last part of the race. January, the badminton team will For Zohri, the vaccine could Zohri will compete in the men’s head to Europe in March to par- mean a boost in confi dence as the 100 m at the Olympics, and he ticipate in the Swiss Open and young gun has already secured aims to fi nish the race in under prestigious All England badmin- a spot to compete at the upcom- 10 seconds. His personal best is ton tournaments. ing Tokyo Olympics. However, 10.03, which secured him a bronze Meanwhile, Indonesia’s top tryouts before the big event have medal in the 2019 Seiko Golden tennis players, Aldila Sutjiadi, Be- yet to be held, and he has not re- Grand Prix in Osaka, Japan. atrice Gumulya and Jessy Romp- ceived any information about Athletes are part of the gov- ies, are currently in the United competing in tournaments in the ernment’s second-phase vaccine States to compete at several low- near future. recipients, along with the elderly level tournaments. “Right now, I’m just focusing and public workers. The local soccer and basketball on training, especially sharpen- Some observers, however, have leagues have been granted per- ing the technical aspects,” he said. questioned the urgency of in- mission to resume competition, “We can’t [compete] because of oculating athletes. Epidemiolo- which will commence in March. the coronavirus. I just treat every gist Dicky Budiman from Griffi th In the meantime, athletes par- practice like a real competition; University in Australia, for exam- ticipating in the Tokyo Olympics that’s what keeps me going.” ple, has reiterated the urgency of in July and August have been al- An entire year without the focusing the vaccine drive on the lowed to visit Japan to train for competitive pressure of a tourna- elderly, people with comorbidi- the upcoming Games, Reuters re- ment has taken a toll on Indone- ties and essential workers. ported. Japan’s emergency decla- sia’s athletes. Zohri conceded that Nevertheless, the Health Min- ration is set to be lifted on March sometimes laziness had crept in, istry placed athletes in the same 7, with the travel ban on foreign but thanks to a program designed group, noting that they traveled athletes removed shortly after.
Load more

Recommended publications
  • A Menace Wrapped in a Protein: Zika and the Global Health Security Agenda
    See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/320677119 Title: A MENACE WRAPPED IN A PROTEIN: ZIKA AND THE GLOBAL HEALTH SECURITY AGENDA Technical Report · September 2017 DOI: 10.13140/RG.2.2.25050.85443 CITATIONS READS 2 129 5 authors, including: Helen Epstein Wilmot James Bard College Columbia University 28 PUBLICATIONS 925 CITATIONS 5 PUBLICATIONS 15 CITATIONS SEE PROFILE SEE PROFILE Ángel G Muñoz Lawrence Stanberry Columbia University Columbia University 121 PUBLICATIONS 694 CITATIONS 238 PUBLICATIONS 7,326 CITATIONS SEE PROFILE SEE PROFILE Some of the authors of this publication are also working on these related projects: Climate informed malaria prevention, control and elimination View project ENACTS (Enhanced National Climate Services) View project All content following this page was uploaded by Ángel G Muñoz on 27 October 2017. The user has requested enhancement of the downloaded file. Title: A MENACE WRAPPED IN A PROTEIN: ZIKA AND THE GLOBAL HEALTH SECURITY AGENDA Authors: Helen Epstein, Wilmot James, Ángel G. Muñoz, Lawrence Stanberry & Madeleine C. Thomson. Reference: Columbia GHS&D Working Group Papers 2017-01 Date: September, 2017 Place: Columbia University Medical Center, Morgan Stanley Children’s Hospital, Office 102, 3959 Broadway CHC 1-102, New York City NY 10032, USA. Copyright: This work is licensed under the Creative Commons Attribution-NonCommercial- ShareAlike 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/. A MENACE WRAPPED IN A PROTEIN1: ZIKA AND THE GLOBAL HEALTH SECURITY AGENDA Preface Stephen Nicholas & Marc Grodman… i 1.Zika: Implications for Global Health Security Helen Epstein… 1 2.Zika Pathogenesis, Diagnosis and Vaccines Lawrence Stanberry… 12 3.Climate Change, the Environment and the Zika Outbreak Madeleine C.
    [Show full text]
  • The COVID-19 Infodemic* 07 08
    01 Editorial 02 03 04 05 06 The COVID-19 Infodemic* 07 08 1 1 2 3 4 09 Sebastián García-Saisó, Myrna Marti, Ian Brooks, Walter H. Curioso, Diego González, 10 Victoria Malek,1 Felipe Mejía Medina,1 Carlene Radix,5 Daniel Otzoy,6 Soraya Zacarías,7 11 1 1 12 Eliane Pereira dos Santos and Marcelo D’Agostino 13 14 15 16 Suggested citation García-Saisó S, Marti M, Brooks I, Curioso WH, González D, Malek V, et al. The COVID-19 Infodemic. Rev Panam Salud Publica. 2021;45:e56. https://doi.org/10.26633/RPSP.2021.56 17 18 19 20 On 15 February 2020, during the Munich Security Conference The infodemic can negatively impact health and well-being 21 (1), the Director of the World Health Organization (WHO), Dr. and can also polarize public debate. Campaigns against public 22 Tedros Adhanom Ghebreyesus, stated that the fight against health measures, inaccurate or falsified epidemiological data, and 23 the COVID-19 pandemic was accompanied by a fight against fake or biased evidence can potentially alter people’s behavior. 24 an “infodemic”, leading to a series of initiatives by the WHO This puts extra pressure on health systems, as it undermines the 25 and other organizations to face this challenge. This situation is scope and efficiency of the various health intervention programs. 26 not new: others have occurred during other health emergen- The main factors contributing to the development of the info- 27 cies, but never one of the current magnitude, resulting from the demic are associated with a lack of digital literacy programs (5) 28 increased use of digital applications (2).
    [Show full text]
  • Covid and That Other Pandemic—Lies T’S Been a Long Weekend
    comment “NHS staff's TikTok dances are feeding the hostile social media beast” DAVID OLIVER “To establish trust, we need transparency and everyday language” HELEN SALISBURY PLUS Covid’s impact on defensive medicine; a child’s right not to be hit CRITICAL THINKING Matt Morgan Covid and that other pandemic—lies t’s been a long weekend. The growing number must also speak no evil. Instead, they scream it at of my colleagues self-isolating has led to the top of their lungs. Half of the profi les pushing the increasing gaps in our rota. Combined with the unethical, dangerous, and discredited case for herd unwelcome return of covid-19 to intensive care immunity through the Great Barrington Declaration Iunits throughout Europe, the long hard summer were artifi cial, bot-like accounts, amplifi ed by social is morphing into the longer, harder winter. I let out a media above the consensus view. slow exhale as I sink into my sofa after arriving home As doctors, nurses, and patients, we must move late on a Sunday night. Time to recharge, relax, and beyond blaming individuals who respond to these refl ect—but a million voices are shouting at me. bad ideas and bad incentives: instead, let us task A video on YouTube tells me that the covid tests I the companies with taking responsibility for their ordered were false. A Facebook post proclaims that output. If not, they can fund the intensive care masks are simply a tool of government oppression. beds, the staff sickness gaps, and the tissues Twitter advises me that those death certifi cates I’ve to wipe away tears when their broadcast written were lies.
    [Show full text]
  • COVID-19 Speaker Key: MH Dr Margaret Harris TAG Dr Tedros
    COVID-19 Speaker key: MH Dr Margaret Harris TAG Dr Tedros Adhanom Ghebreyesus TU Tu MR Dr Michael Ryan VA Vadia MK Dr Maria Van Kerkhove DI Diego IM Imogen CR Charles CO Corinne CS Costas MH Good morning, afternoon and evening. Welcome, everybody, and thank you for joining this latest WHO press briefing on COVID-19. As most of you are aware, we here at WHO headquarters in Geneva are practising physical distancing as one measure to stop COVID-19 transmission so from this week and onwards these press briefings will be held as virtual meetings with very few of us in the room. You can see we're well apart. Just some housekeeping; if you've joined online please use the raise your hand icon to indicate you want to ask a question. If you've joined by phone press # 9 on your keypad to ask a question. Listen out for your name. Sometimes names are not clear when we get them so my apologies in advance. We have here today three people who for most of you need no introduction. We have WHO director-general, Dr Tedros, our executive director of our emergency programme, Dr Mike Ryan, and our technical lead, Dr Maria Van Kerkhove. Dr Tedros will provide some opening remarks, then we'll open it for questions. I'd like to remind you we can only have one question per journalist. We've got limited time. This is a very busy time for everybody so please respect that. There are a lot of you and we want to give everybody a fair chance.
    [Show full text]
  • Takeda Vaccines Innovation for Global Impact
    TAKEDA VACCINES INNOVATION FOR GLOBAL IMPACT CHOO BENG GOH, MD Regional Lead for Medical Affairs Asia, Global Vaccine Business Unit OUR MISSION Develop and deliver innovative vaccines that tackle the toughest problems in public health and improve the lives of people around the world 2 WE HAVE BUILT A GLOBAL VACCINE BUSINESS UPON A STRONG FOUNDATION IN JAPAN Global pivotal Phase 3 PARTNERSHIPS clinical trial of dengue ACQUISITIONS Polio vaccine vaccine candidate initiated: candidate Japan vaccine business Global vaccine business Dengue vaccine 20,100 participants in 8 Bill & Melinda Gates Foundation established established candidate countries in 2 regions Norovirus vaccine Zika vaccine candidate 1946 2012 candidate 2016 U.S. Government‐ BARDA 1947 2010 2014 2018 1st Takeda Multiple vaccine products Partnered with Japan Phase 3 clinical trial results of manufactured vaccine manufactured internally government to develop and dengue vaccine candidate is and marketed in Japan supply pandemic influenza expected in H2 FY18 vaccines for people in Japan 3 THE VACCINE MARKET IS AN ATTRACTIVE PLACE FOR INVESTMENT Vaccine sales growth projected at 7.1% between Durability in sales with limited impact 2017 and 2024, reaching $44.6 billions in 20241 of patent expiry Blockbuster potential in newly launched vaccines Threat of emerging and existing infectious diseases with epidemic potential 1 Evaluate Pharma report 2018 4 OUR STRATEGY Develop vaccines with global BUILD A GLOBAL TACKLE Target the greatest opportunity relevance and business potential PIPELINE
    [Show full text]
  • COVID-19 Vaccination Strategy in China: a Case Study
    Article COVID-19 Vaccination Strategy in China: A Case Study Marjan Mohamadi 1,†, Yuling Lin 1,*,† ,Mélissa Vuillet Soit Vulliet 1,†, Antoine Flahault 1, Liudmila Rozanova 1 and Guilhem Fabre 2 1 Institute of Global Health, University of Geneva, 1211 Geneva, Switzerland; [email protected] (M.M.); [email protected] (M.V.S.V.); antoine.fl[email protected] (A.F.); [email protected] (L.R.) 2 Department of Chinese, UFR 2, Université Paul Valéry Montpellier 3, 34199 Montpellier, France; [email protected] * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: The coronavirus disease 2019 (COVID-19) outbreak in China was first reported to the World Health Organization on 31 December 2019, after the first cases were officially identified around 8 December 2019. However, the case of an infected patient of 55 years old can probably be traced back on 17 November. The spreading has been rapid and heterogeneous. Economic, political and social impacts have not been long overdue. This paper, based on English, French and Chinese research in national and international databases, aims to study the COVID-19 situation in China through the management of the outbreak and the Chinese response to vaccination strategy. The coronavirus disease pandemic is under control in China through non-pharmaceutical interventions, and the mass vaccination program has been launched to further prevent the disease and progressed steadily with Citation: Mohamadi, M.; Lin, Y.; 483.34 million doses having been administered across the country by 21 May 2021. China is also Vulliet, M.V.S.; Flahault, A.; acting as an important player in the development and production of SARS-CoV-2 vaccines.
    [Show full text]
  • NOV 2020 RR Updated CREAM.Indd
    RESEARCH REPORTS Volume LXXXI November 2020 published by RESEARCH REPORTS AIER publishes over 100 articles per month that are distributed in digital form. Research Reports contains Business Conditions Monthly plus 12 of the most representative, chosen here for popularity, variety, and relevance. These articles are often reprinted in venues around the web, including Seeking Alpha, Intellectual Takeout, Mises Brasil, and dozens of other outlets. To read all of them, go to www.aier.org Business Conditions Monthly ROBERT HUGHES 1 The Year of Disguises ROGER W. KOOPS 9 AIER Hosts Top Epidemiologists, Authors of the Great Barrington Declaration AIER STAFF 20 The Great Barrington Declaration and Its Critics JENIN YOUNES 22 Reddit’s Censorship of The Great Barrington Declaration ETHAN YANG 25 The Sketchy Claims of the Case for a Mask Mandate PHILLIP W. MAGNESS 28 Lockdown: The New Totalitarianism JEFFREY A. TUCKER 32 What’s Behind The WHO’s Lockdown Mixed-Messaging STACEY RUDIN 35 Covid Is Not Categorically Different DONALD J. BOUDREAUX 41 The Devastating Economic Impact of Covid-19 Shutdowns AMELIA JANASKIE & PETER C. EARLE 43 Will Things Ever Go Back To Normal? JOAKIM BOOK 53 Does Anyone Trust the Fed? THOMAS L. HOGAN 56 QE Goes Global COLIN LLOYD 58 BUSINESS CONDITIONS MONTHLY Robert Hughes Senior Research Fellow AIER’s Leading Indicators Index Improves Again in October The U.S. economy continued to recover in October from the historic plunge in economic activity in the first half of the year. However, the pace of recovery in some areas has slowed. Furthermore, fallout from continuing restrictions (small business and personal bankruptcies) as well as the potential for renewed lockdown policies remain ongoing threats to future growth.
    [Show full text]
  • The Covid–19 Pandemic and Haemoglobin Disorders
    THE COVID–19 PANDEMIC AND HAEMOGLOBIN DISORDERS VACCINATIONS & THERAPEUTIC DRUGS An Informational Guide from the Thalassaemia International Federation (TIF) Prepared by: Dr Androulla Eleftheriou, Executive Director, TIF Last Updated: 12 May 2020 VACCINATIONS & THERAPEUTIC DRUGS Introduction It is important to note that there are currently no FDA1 or EMA2-approved or even recommended agents for the treatment of the novel coronavirus (COVID-19), for which the World Health Organization (WHO) declared as pandemic on Wednesday 11th of March 2020. Any agent being used at this time is being administered in an experimental setting under controlled conditions. Thalassaemia International Federation (TIF) has made an effort to compile a list of studies/clinical trials for treatment and vaccines, which is by no means exhaustive as this situation is extremely labile and research in this area is dramatically intensified. New information is anticipated to be added to this guide which is prepared exclusively for TIF’s global thalassemia community. The viral genome was mapped very soon as rom early January 2020 and shared globally. In February 2020, the WHO published an overview of the potential therapeutic candidates for the treatment of COVID-19. The document outlines 76 regimens that have been proposed (as of February 17, 2020) for the treatment of patients infected with the virus. Thirty-eight of these candidates are in the preclinical state with minimal information available on their proposed mechanism, uses, doses routes, or planned trials. Sixteen of the remaining regimens contain an interferon-based product. The rest include a variety of antimicrobials, corticosteroids, convalescent plasma, and biologics. The Director-General of the WHO, Mr Tedros Adhanom, stated on the 10th of April 2020, that more than 70 countries have joined WHO’s trial to accelerate research on effective treatments and 20 Institutions and companies ‘are racing to develop a vaccine’.
    [Show full text]
  • HPV Vaccine Update
    Dengue modeling Andrea Vicari Comprehensive Family Immunization Unit Family, Gender and Life Course Department Outline • Framing modeling within policy cycle • Purposes of infectious disease modeling • Overview of dengue modeling • Final considerations Five stages of a policy cycle Agenda setting • Problem recognition Policy formulation • Proposal of solution Decision-making • Choice of solution Policy implementation • Putting solution into effect Policy evaluation • Monitoring results Howlett & Ramesh, Studying public policy: Policy cycles and policy subsystems, 1995 Identify the decision situation and A decision- understand objectives analysis process Identify alternatives flowchart Decompose and model the problem: 1. Model of problem structure 2. Model of uncertainty 3. Model of preferences Choose best alternatives Sensitivity analysis Is further YES analysis necessary? NO Implement chosen alternative Clemen and Reilly, Making hard decisions, 2002. Main purposes of infectious disease modeling • To understand fundamental driving forces of disease ecology and epidemiology • To measure epidemiological parameters that cannot be directly measured with field or laboratory data • To make predictions of future disease incidence under specified conditions • To forecast impact of different prevention/control measures and their combination Adapted from: WHO-VMI Dengue Vaccine Modeling Group, PLoS Negl Trop Dis 2012, 6:e1450 Classical Ross-Macdonald model for malaria transmission (1) Classical Ross-Macdonald model for malaria transmission (2) m
    [Show full text]
  • Icn at the 73Rd World Health Assembly, 2020 and the 148Th Who Executive Board, 2021
    INTERNATIONAL COUNCIL OF NURSES ICN AT THE 73RD WORLD HEALTH ASSEMBLY, 2020 AND THE 148TH WHO EXECUTIVE BOARD, 2021 Prepared by Erica Burton - ICN Senior Advisor, Nursing & Health Policy TABLE OF CONTENTS INTRODUCTION .............................................................................................................3 OPENING OF THE RESUMED WHA73 ........................................................................3 Address by WHO Director-General Dr Tedros Adhanom Ghebreyesus WHA73 3 Keynote address by Her Royal Highness Princess Muna Al-Hussein of Jordan (HRH), WHO Patron for Nursing & Midwifery .........................................................4 OPENING OF THE EB148 ..............................................................................................5 Address by WHO Director-General Dr Tedros Adhanom Ghebreyesus .............5 COVID-19 response ..................................................................................................5 WHO’s work in health emergencies .......................................................................6 Strengthening WHO’s global emergency preparedness and response .......6 .....Strengthening preparedness for health emergencies: implementation of the International Health Regulations (2005) .................................................................7 Interim progress report of the Review Committee on the functioning of the International Health Regulations (2005) during the COVID-19 response ............7 Mental health preparedness and response for the COVID-19
    [Show full text]
  • Dengue Vaccine: Global Development Update
    REVIEW ARTICLE Asian Pacific Journal of Allergy and Immunology Dengue vaccine: Global development update Eakachai Prompetchara,1,2,3 Chutitorn Ketloy,3,4 Stephen J. Thomas,5 Kiat Ruxrungtham4,6 Abstract The first licensed dengue vaccine, CYD-TDV (Dengvaxia®), has received regulatory approval in a number of countries. However, this vaccine has some limitations. Its efficacy against DENV2 was consistently lower than other serotypes. Protective efficacy also depended on prior dengue sero-status of the vaccinees. Lower efficacy was observed in children with < 9 years old and dengue-naïve individuals. More importantly, risk of hospitalization and severe dengue was in- creased in the youngest vaccine recipients (2-5 years) compared to controls. Thus, the quest of a better vaccine candi- date continues. There are two live-attenuated vaccine candidates currently testing in phase III trial including DENVax, developed by US CDC and Inviragen (now licensed to Takeda) and TV003/TV005, constructed by US NIAID. In addi- tion, there are several phase I–II as well as preclinical phase studies evaluating vaccines for safety and immunogenicity, this include other live-attenuated platform/strategy, purified-inactivated viruses formulated with adjuvants, DNA vac- cine, subunit vaccine, viral vector and also heterologous prime/boost strategies. The major difficulties of dengue vaccine development are included the lack of the best animal model, various immune status of individual especially in endemic areas and clear cut off of protective immunity. Several research and development efforts are ongoing to find a better effec- tive and accessible dengue vaccine for people needed. Key words: Dengue vaccine, Live-attenuated virus, Inactivated virus, DNA vaccine, Subunit vaccine, Heterologous prime- boost From: is the result of worldwide transportation and travel, increas- 1 Department of Biochemistry and Microbiology, ing urbanization, as well as climate change which support Faculty of Pharmaceutical Sciences, Chulalongkorn University, 3 Bangkok, Thailand the spreading of Aedes mosquitoes.
    [Show full text]
  • COVID-19 Vaccine-Mediated Enhanced Disease (VMED)
    COVID-19 Vaccine-Mediated Enhanced Disease and Vaccine Effectiveness in the Vaccine Safety Datalink VSD Study #1341 PROTOCOL VERSION: 1.2 DATE: 27 April 2021 KEY STUDY STAFF Marshfield Clinic Research Institute (MCRI) Principal Investigator Edward Belongia, MD Co-Investigators Thomas Boyce, MD, MPH James Donahue, DVM, PhD Dave McClure, PhD Biostatistician Burney Kieke Jr., MS Project Managers Kayla Hanson, MPH Hannah Berger, MPH Data Manager Erica Scotty, MS Project Administrator Bobbi Bradley, MPH, MBA Vaccine Safety Datalink Collaborating Site Investigators and Project Managers Denver Health Joshua Williams, MD Jonathan Block, MEd, PMP Harvard Pilgrim Katherine Yih, PhD, MD Jessica LeBlanc, MPH HealthPartners Malini DeSilva, MD, MPH Leslie Kuckler, MPH Kaiser Permanente Matt Daley, MD Colorado Jo Ann Shoup, PhD Kaiser Permanente Nicky Klein, MD, PhD Northern California Kristin Goddard, MPH (AIM 2) Kaiser Permanente Stephanie Irving, MHS Northwest Tia Kauffman, MPH Kaiser Permanente Bruno Lewin, MD Southern California Cheryl Carlson, MPH (AIM 2) Denison Ryan, MPH Kaiser Permanente Lisa Jackson, MD, MPH Washington Erika Kiniry, MPH Centers for Disease Control and Prevention (CDC) Investigators Immunization Safety Jonathan Duffy, MD, MPH Office Michael McNeil, MD, MPH COVID-19 VE Team TBN Page ii PROTOCOL CHANGE HISTORY Version/Date Summary of Change 1.0/26 March 2021 Original protocol 1.1/21 April 2021 Minor revisions to eligibility criteria, exposure classification, and covariates 1.2/27 April 2021 Minor revisions to data lag and Aim 2 endpoints PROTOCOL SYNOPSIS Title: COVID-19 VMED and Vaccine Effectiveness in the VSD Short name: COVID-19 VMED/VE Study Rationale Vaccine-mediated enhanced disease (VMED) can result from immune complex formation and Th2 biased cellular immune response when vaccinated individuals become infected with the target pathogen.
    [Show full text]